Introduction

Our department is responsible specifically for complex cases resulting from trauma. Our experience does not want to add what has been clearly demonstrated by multicenter studies on the efficacy of rivaroxaban but aims to demonstrate how the use of this molecule was effective also in mega-prosthesis and how it has proven to be flexible and safe in dealing with difficulties and surgical complications more common in such difficult cases.

Introduction

The development of new megaprosthesis for the treatment of large bone defects has offered important opportunities to orthopedic oncologic surgeons for the replacement of skeletal segments such as the long bones of the upper and lower limbs and the relative joints. Our experience, treating non union and severe bone loss, has brought us, sometimes, to be confronted with the reality of some failures after unsuccessful attempts to reconstruct. Faced with certain radiological and / or clinical drastic situations we wanted to apply the principles of Biological Chamber and oncologic surgery with megaprosthetic replacement solutions. We implanted megaprosthesis with either 1 step or 2 steps (previous antibiotated spacer) technique depending on the septic patient conditions. The aim of this study is to retrospectively evaluate both clinical and radiological outcomes in patients underwented to a lower limb megaprosthesis implant and complications were recorded.

INTRODUCTION

The hip arthroplasty implant is currently growing up both in orthopedic and trauma practice. This increases the frequency of prosthesis revision due to implant loosening often associated with periprosthetic osteolysis that determine the failure and lead to a loss of bone substance.

Nowadays there are numerous biotechnologies seeking to join or substitute the autologous or omologous bone use. These biotechnologies (mesenchymal stromal cells, growth factors and bone substitutes) may be used in such situations, however, the literature doesn't offer class 1 clinical evidences in this field of application.

Background: Despite of advanced implant modifications and surgical techniques, internal fixation of proximal femur fractures in osteoporotic elderly is conditioned by high rate of complicated healing and implant failure. The deterioration in micro architecture and the loss in mechanical properties of trabecular bone due to impaired bone turnover must be treated. Teriparatide(TPTD) has been demonstrated to improve of new bone formation in both trabecular and cortical envelopes and thus bone strength. Moreover in a number of fracture models on anims stimulates the healing process generating larger total callus volume. The aim of this study was to determine if bone anabolic agent (TPTD) may enhance the repair of femoral neck fractures in osteoporotic elderly synthesized with internal fixation and prevent complications.

Study Design: 31 compliant females between 57 and 95 years-old presenting a lateral femoral neck fracture was considered. At admission in orthopaedic unit they were undergone to haematochemical exams extended to bone turnover markers, lumbar and contralateral femoral BMD measured by DXA and x-rays of dorsal-lumbar spine. They were divided in two subgroups on the basis of concomitant vertebral compression fracture (VCF) discovered. To the patients with VCF was administrated daily subcutaneous injection of 20 microgr. of TPTD (TPTD group). Both groups received 1g of calcium carbonate and 1200 IU of colecalciferol daily from the first post-operative week. All the patients repeated x-rays of affected segments and bone turnover markers at 1,3,6 months. The pain was detected through a self-reported visual analogue scale (VAS). The functional outcome was evaluated in term of hospitalization, of walking on two crutches and their abandon.

Results: At admission serum 25(OH) vitamin D concentration was at lower levels but the supplementation was sufficient to normalize even if in TPTD group it remained lower than control. In TPTD group the bone formation markers were significantly increased at 1st month and peaked at 3rd month without an increase in bone resorption markers. In TPTD group the callus formation was radiologically evident from 1st month followed by consolidation within 3rd month for all. While in control group the fracture repair was less detectable at 3rd month with heterogeneous trend: one needed a re-operation, four were afflicted by delayed union and another one by VCF. Moreover earlier walking and abandon of crutches in TPTD group was related to significant decrease of pain. At 6th month BMD is significantly increased only in TPTD group.

Conclusions: In osteoporotic femoral neck fractures the demonstration of enhanced repair, the stability of the osteosynthesis, the pain relief and the recovery of autonomy in walking obtained with adjuvant anabolic therapy (TPTD) opens new therapeutic perspectives.